user
menu
letter
Sign InRegister
langEnglisharrow

Tools for ADC PK Analysis——Anti-payload antibodies

Product Features
High Purity (>95%): SDS-PAGE & SEC-MALS validation
High affinity: Verified by ADCs binding assay
High sensitivity: Specifically recognizes small molecule toxins
Comprehensive data:Provides thorough PK validation data references.
Complete technical support: Assists in establishing PK methodologies.
Click here to view data >>
Research Applications
ELISA PK/PD studies on ADCs in preclinical and clinical
Background
Antibody-drug conjugates (ADCs) consist of monoclonal antibodies (mAbs), cytotoxic payloads, and linkers. This complexity engenders heightened drug heterogeneity, thereby rendering the pharmacokinetic (PK) studies of ADCs notably intricate.
PK studies entail the meticulous examination and characterization of drug absorption, distribution, metabolism, and excretion (ADME) processes. Analytes for ADCs typically encompass total antibodies (both conjugated and unconjugated with cytotoxic payloads, DAR≥0); conjugated antibodies (antibody conjugated to payload, DAR≥1), the antibody-conjugated drug, free drugs, and their analogs.
The quantification of total antibodies and conjugated antibodies commonly employs ELISA (Enzyme-linked Immunosorbent Assay), while the analysis of antibody-conjugated drugs, free drugs, and their metabolites frequently involves LC-MS (Liquid Chromatograph Mass Spectrometer).
To support your ADCs PK studies in preclinical or clinical stages, we now offer multiple anti-payload antibodies with high affinity. These antibodies specifically bind to DXD, MMAE, DM-1, SN38, Eribuli*, and other molecules, ideal for ELISA assays in your ADC PK studies!
Type Analyte Detail Typical Method
Total Antibody Conjugated, partially unconjugated, and fully unconjugated (DAR ≥ 0) Ligand Binding Assay
Conjugated Antibody Antibody with minimum DAR ≥ 1 Ligand Binding Assay
Antibody-conjugated Drug Total small-molecule drug conjugated to Antibody Affinity LC-MS / Ligand Binding Assay
Unconjugated Drug Small molecule drug not conjugated to antibody LC-MS
Total Drug Total unconjugated and conjugated Drug LC-MS

ADC molecule type and typical analytical methods for evaluation. 1

Different LBA formats to analyze ADCs in serum

Different LBA formats to analyze ADCs in serum 2

Product List

Anti-payload Antibody
Anti-idiotypic Antibody
Cat. No.MoleculeProduct DescriptionOrder Now
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order

Assay Data

Case study: PK method development and sample Detection
Immobilized with anti-DXD antibody for quantitative detection of T-Dxd concentration in serum.
Immobilized with anti-DXD antibody for quantitative detection of T-Dxd concentration in serum.

Immobilized Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) at 1 μg/mL, add Trastuzum*b deruxtecan in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Immobilized with HER2, and adds Biotinylated anti-DXD antibody as the secondary antibody for quantitative measurement of T-Dxd concentration in serum.
Immobilized with HER2, and adds Biotinylated anti-DXD antibody as the secondary antibody for quantitative measurement of T-Dxd concentration in serum.

Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Trastuzum*b Deruxtecan in the 100% Human Serum and then add Biotinylated Anti-DXD Antibody, Mouse IgG1, Avitag (Cat. No. DXD-BVM807) at 0.05 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).

Immobilized with anti-MMAE antibody for quantitative detection of RC48 concentration in serum.
Immobilized with anti-MMAE antibody for quantitative detection of RC48 concentration in serum.

Immobilized Mouse Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 50% Mouse serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Immobilized with anti-DM1 antibody for quantitative detection of Trastuzum*b-DM1 concentration in serum.
Immobilized with anti-DM1 antibody for quantitative detection of Trastuzum*b-DM1 concentration in serum.

Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 5 μg/mL, add Trastuzum*b-DM1 in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Purity over 90% verified by SEC-MALS
Purity over 90% verified by SEC-MALS

The purity of Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 (Cat. No. DXD-M684) is more than 90% and the molecular weight of this protein is around 135-160 kDa verified by SEC-MALS.

Purity over 90% verified by SEC-MALS

The purity of Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) is more than 90% and the molecular weight of this protein is around 134-163 kDa verified by SEC-MALS.

High affinity with ADCs verified by ELISA
High affinity with ADCs verified by ELISA

Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) with a linear range of 0.1-4 ng/mL (Routinely tested).

High affinity with ADCs verified by ELISA

Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) with a linear range of 0.1-2 ng/mL (QC tested).

High affinity with ADCs verified by ELISA

Immobilized ADC-DM4 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) with a linear range of 0.20-6.25ng/mL (Routinely tested).

High affinity with ADCs verified by ELISA

Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind HRP conjugated Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1 (Cat. No. DXD-PLM684) with a linear range of 0.5-31 ng/mL (Routinely tested).

Cross Verification
Cross Verification

ELISA binding of Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) with Trastuzumab Deruxtecan, IgG1-MMAF, Sacituzumab Govitecan, Disitamab Vedotin (RC48), Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibody respectively. The coating antibody was Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Trastuzumab Deruxtecan, IgG1-MMAF, Sacituzumab Govitecan, Disitamab Vedotin (RC48), Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ fragment specific (min X Bov, Hrs, Ms Sr Prot) (Jackson, Cat. No. 109-035-098) used at 1:12000 concentration. Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) is specific to Disitamab Vedotin (RC48), Trastuzumab MMAE and IgG1-MMAF, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecan and Trastuzumab-DM1 (Routinely tested).

Competitive binding assay of monomethyl auristatin E and anti-MMAE antibody
Competitive binding assay of monomethyl auristatin E and anti-MMAE antibody

Serial dilutions of Monomethyl auristatin E were added into Monoclonal Anti-MMAE specific Antibody, Rabbit IgG (M1H05) (Cat. No. MME-MY2198a.): Disitamab Vedotin (RC48) binding reactions. The half maximal inhibitory concentration (IC50) is 2.642 μg/mL (Routinely tested).

Anti-Idiotypic Antibody and Development Service

Anti-idiotypic antibodies are antibodies that target the variable region of another antibody to produce specific binding. These antibodies are widely used in drug development: they can be used as an important reference standard for immunogenicity analysis or can be developed to specifically detect antibody drug levels for pharmacokinetic studies.
Anti-Idiotypic Antibody
We have developed a series of anti-idiotype antibodies with high affinity, high specificity and high sensitivity for immunogenicity analysis and pharmacokinetics studies.
Anti-idiotype Antibody Product List
View More Validation Data
Anti-Idiotypic Antibody Development Service
To meet the more unique needs of our customers, we also provide a one-stop service, starting from antigen preparation to monoclonal / polyclonal anti-idiotype antibody and pharmacokinetic /immunogenicity test kit development.


Hardware Strength

Through the international AAALAC certification, we can standardize the management and use of animals to ensure the quality of antibodies.


Efficient Project Management

Dedicated one-on-one service with our project team with fast response and follow-up.


High Quality Materials

Key reagents for PK/ADA analysis are provided


Multifunctional Service

Services starting from antigen preparation to monoclonal / polyclonal anti-idiotype antibody development and PK/immunogenicity testing kit development.


Compliant with Regulatory Guidelines

We ensure that our PK/ADA test kits are delivered with sensitivity that meets regulatory requirements.

Click to Learn More Information about Anti-Idiotypic Antibody Development Service

Resources

Webinar playback and appointment

‘ADC Potency Analysis and Quality Control Technology Breakthrough’ Webinar Series

ACROBiosystems proudly presents the flagship 'ADC Potency Analysisand Quality Control Technology Breakthrough' live webinar series. This series will systematicallydeconstruct critical aspects ofADC drug development through five coremodules-from potency analysis to quality control technologiesempowering breakthroughs in ADC therapeutics by overcoming keytechnical bottlenecks.

Building the Perfect Antibody-based Therapeutic from Selection to Engineering and Manufacturing

Watch Now

Addressing Challenges in Antibody-Drug Conjugate Development

Here is the brief recap of the webinar:ADCs have the potential to enable 'precision medicine' with a wide market reach.Challenges in ADCs include managing Target Affinity, enhancing payload conjugation, and assessing Payload Delivery in vivo Pharmacokinetics. We can provide high-quality solutions to address these challenges.

Addressing Challenges in Antibody-Drug Conjugate Development

Watch Now

Building the Perfect Antibody-based Therapeutic from Selection to Engineering and Manufacturing

In this webinar, discover how advanced techniques such as Al-driven candidate selection optimization of antibody sequences, and precise conjugation methods come together to address some of the current challenges in antibody-based therapeutics.

Building the Perfect Antibody-based Therapeutic from Selection to Engineering and Manufacturing

Watch Now

Brochure Download

ADC Development
AGLink site-specific onjugation kit
Tools for ADC PK Analysis
Bispecific Antibody Drug Development
Antibody Drug Development

Poster/Application Note Download

Advanced Endocytosis Assays Sensitive Detection and Parameter Optimization for HER2CD20 Antibody Internalization
Development and validation of bioanalytical assays for the quantification of ADC

Related recommendations

Core reagents for Antibody-drug conjugates (ADCs) developmenticon

Biotinylated proteinsicon

Streptavidin (SA) series productsicon

Promotion

Anti-payload antibodies

References

1. Gorovits, B. et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5, 997–1006 (2013).

2. Qin, Q. & Gong, L. Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices. Molecules 27, 1–17 (2022).

FAQ

Q

What ADC analyte can be measured using an anti-payload antibody?

Anti-payload antibodies are commonly used in ligand-binding assays to detect payload-conjugated antibody, typically defined as antibody carrying at least one payload molecule (DAR ≥1). In combination with a target protein or an antibody recognizing the ADC’s antibody component, the assay signal represents ADC molecules retaining both recognized features. This differs from total antibody assays, which also detect partially or fully unconjugated antibody species.
Q

Does an anti-payload antibody recognize free payload and payload-conjugated ADC in the same way?

Not necessarily. Antibody recognition can depend on whether the payload is free, conjugated to a linker, or incorporated into a specific ADC structure. An antibody suitable for ADC quantification should therefore be evaluated against the relevant conjugated ADC rather than selected solely from binding to the free payload. ACROBiosystems provides ADC-binding and competitive-binding data for selected anti-payload antibody clones under the stated assay conditions.
Q

How should different anti-payload antibody clones be compared for ADC PK assay development?

Clones should be compared using the intended ADC, assay format, and sample matrix because payload recognition and cross-reactivity can differ between clones. Selection should consider binding response, quantitative range, matrix tolerance, and discrimination from ADCs containing related or unrelated payloads. ACROBiosystems offers multiple clones and screening panels for selected payloads, including MMAE, MMAF, Eribulin, PBD, and Doxorubicin.
Q

When should unconjugated, biotinylated, or HRP-conjugated anti-payload antibodies be used?

The appropriate format depends on the antibody’s role in the assay. Unconjugated antibodies provide flexibility for assay development, while biotinylated antibodies support streptavidin-based detection and HRP-conjugated antibodies enable direct enzymatic detection. ACROBiosystems offers these formats for selected payload targets, but availability varies by clone and should be confirmed on the individual product page.
Q

Can ACROBiosystems anti-payload antibodies be used to quantify ADCs in serum?

Selected antibodies have been tested in serum-based ELISA configurations. Examples shown on this page include T-DXd detection in human serum using anti-DXd antibodies, RC48 detection in mouse serum using an anti-MMAE/MMAF antibody, and trastuzumab-DM1 detection in human serum using an anti-DM1/DM4 antibody. These results apply to the specified antibodies, ADCs, matrices, reagent concentrations, and assay conditions and do not establish universal matrix compatibility.
Q

Are anti-payload antibody screening panels available for clone selection?

Yes. ACROBiosystems offers anti-payload antibody screening panels for MMAE, MMAF, Eribulin, PBD, and Doxorubicin. These panels allow multiple antibody clones to be evaluated against the intended payload-conjugated ADC and assay conditions before selecting a clone for further assay development.
Q

What conjugate options are available for anti-payload antibodies to support direct and indirect ELISA workflows?

To accommodate automated liquid handling and diverse bioanalytical assay platforms, ACROBiosystems offers anti-payload antibodies in three ready-to-use formats: Unconjugated / Native mAbs: Ideal for surface immobilization as capture reagents in sandwich ELISAs or affinity purification. Biotinylated mAbs (Avi-tag™ / Chemical): Designed for high-sensitivity detection paired with Streptavidin-HRP or streptavidin-coated biosensors. HRP-Conjugated mAbs: Enable single-step direct detection workflows, reducing incubation times and wash steps in high-throughput screening.
Q

How does ACROBiosystems support end-to-end bioanalytical method development for ADC PK and immunogenicity testing?

A: ACROBiosystems provides a complete bioanalytical reagent ecosystem and technical support package: Anti-Payload Portfolio: High-affinity monoclonal antibodies targeting top clinical payloads, including DXD, MMAE, MMAF, DM1, DM4, SN-38, PBD, and Eribulin. High-Purity Target Antigens: SEC-MALS verified recombinant targets (e.g., HER2, TROP2, B7-H3, Claudin 18.2) for sandwich LBA detection. Anti-Idiotypic Antibody Services: Custom anti-ID antibody development and bridging ELISA kit development for total antibody quantification and Anti-Drug Antibody (ADA) screening. Regulatory Reference Data: Complete validation protocols, matrix tolerance references, and Certificate of Analysis (COA) documentation to support IND and BLA regulatory filings.
  • Background
  • Product List
  • Assay Data
  • Anti-Idiotypic Antibody and Development Service
  • Resources
  • Promotion
  • FAQ